Background: We evaluated short- and long-term risks of atrial fibrillation (AF) in patients undergoing surgery for lung cancer (LCA), stratified by treatment modality and time since surgery.
Methods: We used the Korean National Health Insurance Service database to analyze 34,519 LCA patients who underwent surgery between 2010 and 2017. We matched them 1:3 with controls from the general population. Competing risk models were used to calculate cause-specific hazard ratios (csHRs) and 95% CIs for AF, adjusted for demographic and clinical factors. Landmark analyses were conducted at 1 year, 3 years, and 5 years after LCA surgery.
Results: LCA patients had a higher AF risk than controls (csHR, 1.61; 95% CI, 1.53-1.69), peaking within the first year after diagnosis (csHR, 4.06; 95% CI, 3.61-4.58) and gradually declining thereafter but remaining elevated. Patients receiving chemotherapy exhibited sustained elevations in AF risk at 3 years (csHR, 1.44; 95% CI, 1.26-1.65) and 5 years (csHR, 1.40; 95% CI, 1.18-1.66) after surgery. The risk was heightened in patients receiving both chemotherapy and radiation therapy, with consistently high hazard ratios at 3 years (csHR, 2.28; 95% CI, 1.86-2.8) and 5 years (csHR, 2.16; 95% CI, 1.65-2.84) after surgery. In contrast, the AF risk in patients undergoing surgery alone was similar to that of the control group after 3 years.
Conclusions: AF risk in LCA patients varies by treatment modality and time since surgery. Surveillance strategies should be tailored accordingly.
Copyright © 2026 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.